1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Quantitative and qualitative analysis of pulmonary arterial hypertension fibrosis using wide-field second harmonic generation microscopy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We demonstrated that wide-field second harmonic generation (SHG) microscopy of lung tissue in combination with quantitative analysis of SHG images is a powerful tool for fast and label-free visualization of the fibrosis pathogenesis in pulmonary arterial hypertension (PAH). Statistical analysis of the SHG images revealed changes of the collagen content and morphology in the lung tissue during the monocrotaline-induced PAH progression in rats. First order statistics disclosed the dependence of the collagen overproduction on time, the second order statistics indicated tightening of collagen fiber network around blood vessels and their spreading into the alveolar region. Fourier analysis revealed that enhancement of the fiber orientation in the collagen network with PAH progression was followed with its subsequent reduction at the terminating phase of the disease. Proposed approach has potential for assessing pulmonary fibrosis in interstitial lung disease, after lung(s) transplantation, cancer, etc.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: not found
          • Article: not found

          Textural Features for Image Classification

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0

            Improving the reproducibility of biomedical research is a major challenge. Transparent and accurate reporting is vital to this process; it allows readers to assess the reliability of the findings and repeat or build upon the work of other researchers. The ARRIVE guidelines (Animal Research: Reporting In Vivo Experiments) were developed in 2010 to help authors and journals identify the minimum information necessary to report in publications describing in vivo experiments. Despite widespread endorsement by the scientific community, the impact of ARRIVE on the transparency of reporting in animal research publications has been limited. We have revised the ARRIVE guidelines to update them and facilitate their use in practice. The revised guidelines are published alongside this paper. This explanation and elaboration document was developed as part of the revision. It provides further information about each of the 21 items in ARRIVE 2.0, including the rationale and supporting evidence for their inclusion in the guidelines, elaboration of details to report, and examples of good reporting from the published literature. This document also covers advice and best practice in the design and conduct of animal studies to support researchers in improving standards from the start of the experimental design process through to publication.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pulmonary arterial hypertension: pathogenesis and clinical management

              Pulmonary hypertension is defined as a resting mean pulmonary artery pressure of 25 mm Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of pulmonary hypertension that primarily affects the pulmonary vasculature. In PAH, the pulmonary vasculature is dynamically obstructed by vasoconstriction, structurally obstructed by adverse vascular remodeling, and pathologically non-compliant as a result of vascular fibrosis and stiffening. Many cell types are abnormal in PAH, including vascular cells (endothelial cells, smooth muscle cells, and fibroblasts) and inflammatory cells. Progress has been made in identifying the causes of PAH and approving new drug therapies. A cancer-like increase in cell proliferation and resistance to apoptosis reflects acquired abnormalities of mitochondrial metabolism and dynamics. Mutations in the type II bone morphogenetic protein receptor ( BMPR2) gene dramatically increase the risk of developing heritable PAH. Epigenetic dysregulation of DNA methylation, histone acetylation, and microRNAs also contributes to disease pathogenesis. Aberrant bone morphogenetic protein signaling and epigenetic dysregulation in PAH promote cell proliferation in part through induction of a Warburg mitochondrial-metabolic state of uncoupled glycolysis. Complex changes in cytokines (interleukins and tumor necrosis factor), cellular immunity (T lymphocytes, natural killer cells, macrophages), and autoantibodies suggest that PAH is, in part, an autoimmune, inflammatory disease. Obstructive pulmonary vascular remodeling in PAH increases right ventricular afterload causing right ventricular hypertrophy. In some patients, maladaptive changes in the right ventricle, including ischemia and fibrosis, reduce right ventricular function and cause right ventricular failure. Patients with PAH have dyspnea, reduced exercise capacity, exertional syncope, and premature death from right ventricular failure. PAH targeted therapies (prostaglandins, phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and soluble guanylate cyclase stimulators), used alone or in combination, improve functional capacity and hemodynamics and reduce hospital admissions. However, these vasodilators do not target key features of PAH pathogenesis and have not been shown to reduce mortality, which remains about 50% at five years. This review summarizes the epidemiology, pathogenesis, diagnosis, and treatment of PAH.
                Bookmark

                Author and article information

                Contributors
                yaraslau.padrez@ftmc.lt
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                5 May 2022
                5 May 2022
                2022
                : 12
                : 7330
                Affiliations
                [1 ]GRID grid.425985.7, Center for Physical Sciences and Technology, ; Vilnius, Lithuania
                [2 ]GRID grid.17678.3f, ISNI 0000 0001 1092 255X, Institute for Nuclear Problems of Belarusian State University, ; Minsk, Belarus
                [3 ]Central Scientific and Research Laboratory of BelMAPE, Minsk region, Belarus
                [4 ]GRID grid.17678.3f, ISNI 0000 0001 1092 255X, Belarusian State University, ; Minsk, Belarus
                [5 ]State Educational Establishment BelMAPE, Minsk, Belarus
                [6 ]GRID grid.9668.1, ISNI 0000 0001 0726 2490, Department of Physics and Mathematics, , University of Eastern Finland, Institute of Photonics, ; Joensuu, Finland
                Article
                11473
                10.1038/s41598-022-11473-5
                9072392
                35513702
                10dcff56-9d47-404d-be13-b417b030b7c3
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 29 November 2021
                : 25 April 2022
                Funding
                Funded by: Horizon 2020 RISE DiSeTCom
                Award ID: 823728
                Award ID: 823728
                Award ID: 823728
                Award ID: 823728
                Award ID: 823728
                Award ID: 823728
                Award ID: 823728
                Award Recipient :
                Funded by: NATO SPS Programme
                Award ID: #G5777
                Award ID: #G5777
                Award ID: #G5777
                Award ID: #G5777
                Award ID: #G5777
                Award Recipient :
                Funded by: Academy of Finland via Flagship Programme Photonics Research and Innovation
                Award ID: 320166, 343393
                Award ID: 320166, 343393
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Uncategorized
                biophysics,diseases,medical research,signs and symptoms,optics and photonics
                Uncategorized
                biophysics, diseases, medical research, signs and symptoms, optics and photonics

                Comments

                Comment on this article